E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias
{"title":"希腊转移性去势抵抗性前列腺癌患者的医疗资源利用及相关费用","authors":"E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias","doi":"10.1080/14737167.2025.2505726","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.</p><p><strong>Methods: </strong>A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.</p><p><strong>Results: </strong>HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.</p><p><strong>Conclusions: </strong>Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1063-1072"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.\",\"authors\":\"E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias\",\"doi\":\"10.1080/14737167.2025.2505726\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.</p><p><strong>Methods: </strong>A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.</p><p><strong>Results: </strong>HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.</p><p><strong>Conclusions: </strong>Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.</p>\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":\" \",\"pages\":\"1063-1072\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2025.2505726\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2505726","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.
Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.
Methods: A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.
Results: HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.
Conclusions: Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.
期刊介绍：
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
